Global Duchenne Muscular Dystrophy Therapeutics Market 2022 by Company, Regions, Type and Application, Forecast to 2028
The Duchenne Muscular Dystrophy Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Duchenne Muscular Dystrophy Therapeutics market size is estimated to be worth US$ 989.7 million in 2021 and is forecast to a readjusted size of USD 5471 million by 2028 with a CAGR of 27.7% during review period. Hospitals accounting for % of the Duchenne Muscular Dystrophy Therapeutics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Pain Management Drugs segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Duchenne Muscular Dystrophy Therapeutics include Bristol-Myers Squibb, FibroGen (US), Italfarmaco (Italy), Marathon, and NS Pharma (US), etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Duchenne Muscular Dystrophy Therapeutics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Pain Management Drugs
Corticosteroids
Prednisolone
Prednisone
Deflazacort
Market segment by Application, can be divided into
Hospitals
Clinics
Home Care
Market segment by players, this report covers
Bristol-Myers Squibb
FibroGen (US)
Italfarmaco (Italy)
Marathon
NS Pharma (US)
PTC Therapeutics (US)
Pfizer
ReveraGen BioPharma (US)
Santhera Pharmaceuticals (Switzerland)
Sarepta Therapeutics (US)
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Duchenne Muscular Dystrophy Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Duchenne Muscular Dystrophy Therapeutics, with revenue, gross margin and global market share of Duchenne Muscular Dystrophy Therapeutics from 2019 to 2022.
Chapter 3, the Duchenne Muscular Dystrophy Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Duchenne Muscular Dystrophy Therapeutics market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Duchenne Muscular Dystrophy Therapeutics research findings and conclusion, appendix and data source.
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Duchenne Muscular Dystrophy Therapeutics
1.2 Classification of Duchenne Muscular Dystrophy Therapeutics by Type
1.2.1 Overview: Global Duchenne Muscular Dystrophy Therapeutics Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Type in 2021
1.2.3 Pain Management Drugs
1.2.4 Corticosteroids
1.2.5 Prednisolone
1.2.6 Prednisone
1.2.7 Deflazacort
1.3 Global Duchenne Muscular Dystrophy Therapeutics Market by Application
1.3.1 Overview: Global Duchenne Muscular Dystrophy Therapeutics Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Global Duchenne Muscular Dystrophy Therapeutics Market Size & Forecast
1.5 Global Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast by Region
1.5.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Region, (2017-2022)
1.5.3 North America Duchenne Muscular Dystrophy Therapeutics Market Size and Prospect (2017-2028)
1.5.4 Europe Duchenne Muscular Dystrophy Therapeutics Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size and Prospect (2017-2028)
1.5.6 South America Duchenne Muscular Dystrophy Therapeutics Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Duchenne Muscular Dystrophy Therapeutics Market Drivers
1.6.2 Duchenne Muscular Dystrophy Therapeutics Market Restraints
1.6.3 Duchenne Muscular Dystrophy Therapeutics Trends Analysis
2 Company Profiles
2.1 Bristol-Myers Squibb
2.1.1 Bristol-Myers Squibb Details
2.1.2 Bristol-Myers Squibb Major Business
2.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product and Solutions
2.1.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.2 FibroGen (US)
2.2.1 FibroGen (US) Details
2.2.2 FibroGen (US) Major Business
2.2.3 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
2.2.4 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 FibroGen (US) Recent Developments and Future Plans
2.3 Italfarmaco (Italy)
2.3.1 Italfarmaco (Italy) Details
2.3.2 Italfarmaco (Italy) Major Business
2.3.3 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
2.3.4 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Italfarmaco (Italy) Recent Developments and Future Plans
2.4 Marathon
2.4.1 Marathon Details
2.4.2 Marathon Major Business
2.4.3 Marathon Duchenne Muscular Dystrophy Therapeutics Product and Solutions
2.4.4 Marathon Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Marathon Recent Developments and Future Plans
2.5 NS Pharma (US)
2.5.1 NS Pharma (US) Details
2.5.2 NS Pharma (US) Major Business
2.5.3 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
2.5.4 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 NS Pharma (US) Recent Developments and Future Plans
2.6 PTC Therapeutics (US)
2.6.1 PTC Therapeutics (US) Details
2.6.2 PTC Therapeutics (US) Major Business
2.6.3 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
2.6.4 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 PTC Therapeutics (US) Recent Developments and Future Plans
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Product and Solutions
2.7.4 Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Pfizer Recent Developments and Future Plans
2.8 ReveraGen BioPharma (US)
2.8.1 ReveraGen BioPharma (US) Details
2.8.2 ReveraGen BioPharma (US) Major Business
2.8.3 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
2.8.4 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 ReveraGen BioPharma (US) Recent Developments and Future Plans
2.9 Santhera Pharmaceuticals (Switzerland)
2.9.1 Santhera Pharmaceuticals (Switzerland) Details
2.9.2 Santhera Pharmaceuticals (Switzerland) Major Business
2.9.3 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
2.9.4 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Santhera Pharmaceuticals (Switzerland) Recent Developments and Future Plans
2.10 Sarepta Therapeutics (US)
2.10.1 Sarepta Therapeutics (US) Details
2.10.2 Sarepta Therapeutics (US) Major Business
2.10.3 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
2.10.4 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Sarepta Therapeutics (US) Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Duchenne Muscular Dystrophy Therapeutics Players Market Share in 2021
3.2.2 Top 10 Duchenne Muscular Dystrophy Therapeutics Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Duchenne Muscular Dystrophy Therapeutics Players Head Office, Products and Services Provided
3.4 Duchenne Muscular Dystrophy Therapeutics Mergers & Acquisitions
3.5 Duchenne Muscular Dystrophy Therapeutics New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue and Market Share by Type (2017-2022)
4.2 Global Duchenne Muscular Dystrophy Therapeutics Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Application (2017-2022)
5.2 Global Duchenne Muscular Dystrophy Therapeutics Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Duchenne Muscular Dystrophy Therapeutics Revenue by Type (2017-2028)
6.2 North America Duchenne Muscular Dystrophy Therapeutics Revenue by Application (2017-2028)
6.3 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country
6.3.1 North America Duchenne Muscular Dystrophy Therapeutics Revenue by Country (2017-2028)
6.3.2 United States Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
6.3.3 Canada Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
6.3.4 Mexico Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Duchenne Muscular Dystrophy Therapeutics Revenue by Type (2017-2028)
7.2 Europe Duchenne Muscular Dystrophy Therapeutics Revenue by Application (2017-2028)
7.3 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country
7.3.1 Europe Duchenne Muscular Dystrophy Therapeutics Revenue by Country (2017-2028)
7.3.2 Germany Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
7.3.3 France Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
7.3.5 Russia Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
7.3.6 Italy Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue by Type (2017-2028)
8.2 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue by Application (2017-2028)
8.3 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region
8.3.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue by Region (2017-2028)
8.3.2 China Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
8.3.3 Japan Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
8.3.4 South Korea Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
8.3.5 India Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
8.3.7 Australia Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Duchenne Muscular Dystrophy Therapeutics Revenue by Type (2017-2028)
9.2 South America Duchenne Muscular Dystrophy Therapeutics Revenue by Application (2017-2028)
9.3 South America Duchenne Muscular Dystrophy Therapeutics Market Size by Country
9.3.1 South America Duchenne Muscular Dystrophy Therapeutics Revenue by Country (2017-2028)
9.3.2 Brazil Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
9.3.3 Argentina Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue by Type (2017-2028)
10.2 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue by Application (2017-2028)
10.3 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country
10.3.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue by Country (2017-2028)
10.3.2 Turkey Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
10.3.4 UAE Duchenne Muscular Dystrophy Therapeutics Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Duchenne Muscular Dystrophy Therapeutics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Duchenne Muscular Dystrophy Therapeutics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million) by Region (2017-2022)
Table 5. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Region (2023-2028)
Table 6. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 7. Bristol-Myers Squibb Major Business
Table 8. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 9. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. FibroGen (US) Corporate Information, Head Office, and Major Competitors
Table 11. FibroGen (US) Major Business
Table 12. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 13. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Italfarmaco (Italy) Corporate Information, Head Office, and Major Competitors
Table 15. Italfarmaco (Italy) Major Business
Table 16. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 17. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Marathon Corporate Information, Head Office, and Major Competitors
Table 19. Marathon Major Business
Table 20. Marathon Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 21. Marathon Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. NS Pharma (US) Corporate Information, Head Office, and Major Competitors
Table 23. NS Pharma (US) Major Business
Table 24. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 25. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. PTC Therapeutics (US) Corporate Information, Head Office, and Major Competitors
Table 27. PTC Therapeutics (US) Major Business
Table 28. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 29. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Pfizer Corporate Information, Head Office, and Major Competitors
Table 31. Pfizer Major Business
Table 32. Pfizer Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 33. Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. ReveraGen BioPharma (US) Corporate Information, Head Office, and Major Competitors
Table 35. ReveraGen BioPharma (US) Major Business
Table 36. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 37. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Santhera Pharmaceuticals (Switzerland) Corporate Information, Head Office, and Major Competitors
Table 39. Santhera Pharmaceuticals (Switzerland) Major Business
Table 40. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 41. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Sarepta Therapeutics (US) Corporate Information, Head Office, and Major Competitors
Table 43. Sarepta Therapeutics (US) Major Business
Table 44. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 45. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Global Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 47. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 48. Breakdown of Duchenne Muscular Dystrophy Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Duchenne Muscular Dystrophy Therapeutics Players Head Office, Products and Services Provided
Table 50. Duchenne Muscular Dystrophy Therapeutics Mergers & Acquisitions in the Past Five Years
Table 51. Duchenne Muscular Dystrophy Therapeutics New Entrants and Expansion Plans
Table 52. Global Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million) by Type (2017-2022)
Table 53. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Type (2017-2022)
Table 54. Global Duchenne Muscular Dystrophy Therapeutics Revenue Forecast by Type (2023-2028)
Table 55. Global Duchenne Muscular Dystrophy Therapeutics Revenue by Application (2017-2022)
Table 56. Global Duchenne Muscular Dystrophy Therapeutics Revenue Forecast by Application (2023-2028)
Table 57. North America Duchenne Muscular Dystrophy Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 58. North America Duchenne Muscular Dystrophy Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 59. North America Duchenne Muscular Dystrophy Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 60. North America Duchenne Muscular Dystrophy Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 61. North America Duchenne Muscular Dystrophy Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 62. North America Duchenne Muscular Dystrophy Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 63. Europe Duchenne Muscular Dystrophy Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 64. Europe Duchenne Muscular Dystrophy Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 65. Europe Duchenne Muscular Dystrophy Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 66. Europe Duchenne Muscular Dystrophy Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 67. Europe Duchenne Muscular Dystrophy Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 68. Europe Duchenne Muscular Dystrophy Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 69. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 70. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 71. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 72. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 73. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 74. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 75. South America Duchenne Muscular Dystrophy Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 76. South America Duchenne Muscular Dystrophy Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 77. South America Duchenne Muscular Dystrophy Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 78. South America Duchenne Muscular Dystrophy Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 79. South America Duchenne Muscular Dystrophy Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 80. South America Duchenne Muscular Dystrophy Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 81. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 82. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 83. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 84. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 85. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 86. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Duchenne Muscular Dystrophy Therapeutics Picture
Figure 2. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Type in 2021
Figure 3. Pain Management Drugs
Figure 4. Corticosteroids
Figure 5. Prednisolone
Figure 6. Prednisone
Figure 7. Deflazacort
Figure 8. Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Application in 2021
Figure 9. Hospitals Picture
Figure 10. Clinics Picture
Figure 11. Home Care Picture
Figure 12. Global Duchenne Muscular Dystrophy Therapeutics Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 13. Global Duchenne Muscular Dystrophy Therapeutics Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Region (2017-2028)
Figure 15. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Region in 2021
Figure 16. North America Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Europe Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. South America Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Duchenne Muscular Dystrophy Therapeutics Market Drivers
Figure 22. Duchenne Muscular Dystrophy Therapeutics Market Restraints
Figure 23. Duchenne Muscular Dystrophy Therapeutics Market Trends
Figure 24. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 25. FibroGen (US) Recent Developments and Future Plans
Figure 26. Italfarmaco (Italy) Recent Developments and Future Plans
Figure 27. Marathon Recent Developments and Future Plans
Figure 28. NS Pharma (US) Recent Developments and Future Plans
Figure 29. PTC Therapeutics (US) Recent Developments and Future Plans
Figure 30. Pfizer Recent Developments and Future Plans
Figure 31. ReveraGen BioPharma (US) Recent Developments and Future Plans
Figure 32. Santhera Pharmaceuticals (Switzerland) Recent Developments and Future Plans
Figure 33. Sarepta Therapeutics (US) Recent Developments and Future Plans
Figure 34. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Players in 2021
Figure 35. Duchenne Muscular Dystrophy Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 36. Global Top 3 Players Duchenne Muscular Dystrophy Therapeutics Revenue Market Share in 2021
Figure 37. Global Top 10 Players Duchenne Muscular Dystrophy Therapeutics Revenue Market Share in 2021
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 39. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Type in 2021
Figure 40. Global Duchenne Muscular Dystrophy Therapeutics Market Share Forecast by Type (2023-2028)
Figure 41. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Application in 2021
Figure 42. Global Duchenne Muscular Dystrophy Therapeutics Market Share Forecast by Application (2023-2028)
Figure 43. North America Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Type (2017-2028)
Figure 44. North America Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Application (2017-2028)
Figure 45. North America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Country (2017-2028)
Figure 46. United States Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Canada Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Mexico Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Europe Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Type (2017-2028)
Figure 50. Europe Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Application (2017-2028)
Figure 51. Europe Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Country (2017-2028)
Figure 52. Germany Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. France Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. United Kingdom Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Russia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Italy Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Type (2017-2028)
Figure 58. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Application (2017-2028)
Figure 59. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Region (2017-2028)
Figure 60. China Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Japan Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South Korea Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. India Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Southeast Asia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Australia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South America Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Type (2017-2028)
Figure 67. South America Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Application (2017-2028)
Figure 68. South America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Country (2017-2028)
Figure 69. Brazil Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Type (2017-2028)
Figure 72. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Application (2017-2028)
Figure 73. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Country (2017-2028)
Figure 74. Turkey Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. UAE Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source
